Howard Horn Biography and Net Worth

Howard Horn has served as our Executive Vice President and Chief Financial Officer since March 2017. Prior to joining us, Mr. Horn served Biogen Inc. as its Vice President, Business Planning from June 2015 to October 2016, where he led Biogen’s resource allocation processes across all functions and regions. From October 2013 to June 2015, Mr. Horn served as Biogen’s Vice President, Strategic Corporate Finance, where he led Biogen’s corporate capital allocation processes. Mr. Horn previously held positions of increasing responsibility as a consultant in the Pharmaceutical and Medical Products Practice at McKinsey & Company, from 2004 to 2013, and as an equity research analyst in the Life Sciences group at UBS Group AG, from 1999 to 2002. Mr. Horn received his B.A. in Economics from Princeton University and his M.B.A. from the Wharton School of the University of Pennsylvania.

What is Howard Horn's net worth?: The estimated net worth of Howard Horn is at least $1.90 million as of February 23rd, 2023. Mr. Horn owns 230,712 shares of Vir Biotechnology stock worth more than $1,898,760 as of April 26th. This net worth evaluation does not reflect any other investments that Mr. Horn may own. Learn More about Howard Horn's net worth.
How do I contact Howard Horn?: The corporate mailing address for Mr. Horn and other Vir Biotechnology executives is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. Vir Biotechnology can also be reached via phone at 415-906-4324 and via email at [email protected]. Learn More on Howard Horn's contact information.
Has Howard Horn been buying or selling shares of Vir Biotechnology?: Howard Horn has not been actively trading shares of Vir Biotechnology during the last quarter. Most recently, Howard Horn sold 2,248 shares of the business's stock in a transaction on Thursday, February 23rd. The shares were sold at an average price of $25.97, for a transaction totalling $58,380.56. Following the completion of the sale, the chief financial officer now directly owns 230,712 shares of the company's stock, valued at $5,991,590.64. Learn More on Howard Horn's trading history.
Who are Vir Biotechnology's active insiders?: Vir Biotechnology's insider roster includes Ann Hanly (CTO), Howard Horn (CFO), Robert More (Director), Janet Napolitano (Director), Phillip Pang (Insider), Jay Parrish (Insider), Saira Ramasastry (Director), Steven Rice (Insider), Vicki Sato (Director), George Scangos (CEO), and Herbert Virgin (EVP). Learn More on Vir Biotechnology's active insiders.
Are insiders buying or selling shares of Vir Biotechnology?: In the last twelve months, insiders at the sold shares 26 times. They sold a total of 775,857 shares worth more than $17,733,362.17. The most recent insider tranaction occured on April, 3rd when CEO Backer Marianne De sold 72,995 shares worth more than $690,532.70. Insiders at Vir Biotechnology own 18.1% of the company. Learn More about insider trades at Vir Biotechnology.
Information on this page was last updated on 4/3/2024.

Howard Horn Insider Trading History at Vir Biotechnology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/23/2023	Sell	2,248	$25.97	$58,380.56	230,712
2/17/2023	Sell	2,424	$25.29	$61,302.96	232,960
2/17/2022	Sell	2,393	$31.93	$76,408.49
7/13/2020	Sell	30,000	$50.06	$1,501,800.00	177,777
7/2/2020	Sell	20,000	$38.92	$778,400.00	218,677
6/25/2020	Sell	30,000	$50.00	$1,500,000.00	227,777
6/19/2020	Sell	10,000	$40.00	$400,000.00	257,777
6/1/2020	Sell	10,000	$35.10	$351,000.00	274,491

Howard Horn Buying and Selling Activity at Vir Biotechnology

Vir Biotechnology Company Overview

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Today's Range

Now: $8.23

$7.64

$8.27

50 Day Range

MA: $9.94

$7.63

$11.90

2 Week Range

Now: $8.23

$7.61

$27.48

Volume

1,106,008 shs

Average Volume

1,038,808 shs

Market Capitalization

$1.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.41

Biden replacement revealed?

From Paradigm Press | Ad

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report